{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:24:40Z","timestamp":1786922680988,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-000337"],"award-info":[{"award-number":["MOH-000337"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001869-00"],"award-info":[{"award-number":["MOH-001869-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001271-00"],"award-info":[{"award-number":["MOH-001271-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01678-4","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:33:59Z","timestamp":1779521639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aminoglycosides induce immune activation but is insufficient for systemic viral control: a double-blind randomized-controlled clinical trial"],"prefix":"10.1038","volume":"6","author":[{"given":"Punitha","family":"Sivanandam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesa","family":"Syenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne FZ","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy HL","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther S.","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Xin","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine YL","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee Cheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Z.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-1544","authenticated-orcid":false,"given":"Eng Eong","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Kalimuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/cid\/ciad685","volume":"78","author":"EA Meyerowitz","year":"2024","unstructured":"Meyerowitz, E. A. & Li, Y. Review: the landscape of antiviral therapy for COVID-19 in the era of widespread population immunity and omicron-lineage viruses. Clin. Infect. Dis. 78, 908\u2013917 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1678_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2007.12.007","volume":"78","author":"M Bray","year":"2008","unstructured":"Bray, M. Highly pathogenic RNA viral infections: challenges for antiviral research. Antiviral. Res. 78, 1\u20138 (2008).","journal-title":"Antiviral. Res."},{"key":"1678_CR3","doi-asserted-by":"publisher","first-page":"19273","DOI":"10.1074\/jbc.M115.655092","volume":"290","author":"S Hong","year":"2015","unstructured":"Hong, S. et al. Evidence that antibiotics bind to human mitochondrial ribosomal RNA has implications for aminoglycoside toxicity. J. Biol. Chem. 290, 19273\u201319286 (2015).","journal-title":"J. Biol. Chem."},{"key":"1678_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/S0968-0896(01)00034-7","volume":"9","author":"DH Ryu","year":"2001","unstructured":"Ryu, D. H. & Rando, R. R. Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs. Bioorg. Med. Chem. 9, 2601\u20132608 (2001).","journal-title":"Bioorg. Med. Chem."},{"key":"1678_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1367-5931(99)00028-9","volume":"3","author":"F Walter","year":"1999","unstructured":"Walter, F., Vicens, Q. & Westhof, E. Aminoglycoside-RNA interactions. Curr. Opin. Chem. Biol. 3, 694\u2013704 (1999).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1678_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41564-018-0138-2","volume":"3","author":"S Gopinath","year":"2018","unstructured":"Gopinath, S. et al. Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. Nat. microbiol. 3, 611\u2013621 (2018).","journal-title":"Nat. microbiol."},{"key":"1678_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319566121","volume":"121","author":"T Mao","year":"2024","unstructured":"Mao, T. et al. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proc. Natl. Acad. Sci. USA 121, e2319566121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1678_CR8","doi-asserted-by":"crossref","unstructured":"Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016;6.","DOI":"10.1101\/cshperspect.a027029"},{"key":"1678_CR9","first-page":"2025","volume":"ume 16","author":"X Chen","year":"2025","unstructured":"Chen, X., Zou, R., Qian, B.-C., Ni, X. & Xia, H. Recent advances in the biosynthetic pathway and structural modification of gentamicin. Front. in Microbiol. 16, 2025 (2025).","journal-title":"Front. in Microbiol."},{"key":"1678_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1080\/21645515.2021.1891752","volume":"17","author":"A Bovay","year":"2021","unstructured":"Bovay, A., Fuertes Marraco, S. A. & Speiser, D. E. Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses. Hum Vaccin Immunother 17, 2471\u20132481 (2021).","journal-title":"Hum Vaccin Immunother"},{"key":"1678_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-019-0510-7","volume":"25","author":"KR Chan","year":"2019","unstructured":"Chan, K. R. et al. Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection. Nat. Med. 25, 1218\u20131224 (2019).","journal-title":"Nat. Med."},{"key":"1678_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.164","volume":"1","author":"KR Chan","year":"2016","unstructured":"Chan, K. R. et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat. Microbiol. 1, 16164 (2016).","journal-title":"Nat. Microbiol."},{"key":"1678_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","volume":"10","author":"S Kalimuddin","year":"2025","unstructured":"Kalimuddin, S. et al. Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nat Microbiol 10, 374\u2013387 (2025).","journal-title":"Nat Microbiol"},{"key":"1678_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/jac\/39.6.677","volume":"39","author":"CD Freeman","year":"1997","unstructured":"Freeman, C. D., Nicolau, D. P., Belliveau, P. P. & Nightingale, C. H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother. 39, 677\u2013686 (1997).","journal-title":"J. Antimicrob. Chemother."},{"key":"1678_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710\u2013722 (2008).","journal-title":"Immunity"},{"key":"1678_CR16","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1128\/JCM.01799-12","volume":"50","author":"C Domingo","year":"2012","unstructured":"Domingo, C. et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J. Clin. Microbiol. 50, 4054\u20134060 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"1678_CR17","doi-asserted-by":"publisher","first-page":"e3000867","DOI":"10.1371\/journal.pbio.3000867","volume":"18","author":"E Kudo","year":"2020","unstructured":"Kudo, E. et al. Detection of SARS-CoV-2 RNA by multiplex RT-qPCR. PLoS Biol. 18, e3000867 (2020).","journal-title":"PLoS Biol."},{"key":"1678_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMoa2000226","volume":"383","author":"JG Low","year":"2020","unstructured":"Low, J. G. et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N. Engl. J. Med. 383, 452\u2013459 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1678_CR19","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.1106568108","volume":"108","author":"KR Chan","year":"2011","unstructured":"Chan, K. R. et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc. Natl. Acad. Sci. USA 108, 12479\u201312484 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1678_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).","journal-title":"Genome Biol"},{"key":"1678_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nature immunology 15, 195\u2013204 (2014).","journal-title":"Nature immunology"},{"key":"1678_CR22","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545\u201315550 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"1678_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.medj.2023.04.001","volume":"4","author":"EZ Ong","year":"2023","unstructured":"Ong, E. Z. et al. RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication. Med. 4, 353\u201360 e2 (2023).","journal-title":"Med."},{"key":"1678_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nri2436","volume":"8","author":"AG Bowie","year":"2008","unstructured":"Bowie, A. G. & Unterholzner, L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immun. 8, 911\u2013922 (2008).","journal-title":"Nat. Rev. Immun."},{"key":"1678_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. immun. 10, 116\u2013125 (2009).","journal-title":"Nat. immun."},{"key":"1678_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/ni.2370","volume":"13","author":"JC Miller","year":"2012","unstructured":"Miller, J. C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immun. 13, 888\u2013899 (2012).","journal-title":"Nat. Immun."},{"key":"1678_CR27","doi-asserted-by":"crossref","unstructured":"Ashley CL, Abendroth A, McSharry BP, Slobedman B. Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression. Viruses. 2019;11.","DOI":"10.3390\/v11030246"},{"key":"1678_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/emboj\/17.4.1087","volume":"17","author":"M Yoneyama","year":"1998","unstructured":"Yoneyama, M. et al. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP\/p300. Embo. J. 17, 1087\u20131095 (1998).","journal-title":"Embo. J."},{"key":"1678_CR29","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.4049\/jimmunol.1900462","volume":"204","author":"S Gopinath","year":"2020","unstructured":"Gopinath, S., Lu, P. & Iwasaki, A. Cutting edge: the use of topical aminoglycosides as an effective pull in \u201cprime and pull\u201d vaccine strategy. J. of immuno. (Baltimore, Md: 1950) 204, 1703\u20131707 (2020).","journal-title":"J. of immuno. (Baltimore, Md: 1950)"},{"key":"1678_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/intimm\/dxh186","volume":"17","author":"K Takeda","year":"2005","unstructured":"Takeda, K. Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17, 1\u201314 (2005).","journal-title":"Int. Immunol."},{"key":"1678_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","volume":"203","author":"T Querec","year":"2006","unstructured":"Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413\u2013424 (2006).","journal-title":"J. Exp. Med."},{"key":"1678_CR32","doi-asserted-by":"publisher","first-page":"21502","DOI":"10.1074\/jbc.M301476200","volume":"278","author":"S Heinz","year":"2003","unstructured":"Heinz, S. et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J. Biol. Chem. 278, 21502\u201321509 (2003).","journal-title":"J. Biol. Chem."},{"key":"1678_CR33","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1182\/blood-2007-02-072934","volume":"110","author":"AM Lundberg","year":"2007","unstructured":"Lundberg, A. M. et al. Key differences in TLR3\/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 110, 3245\u20133252 (2007).","journal-title":"Blood"},{"key":"1678_CR34","doi-asserted-by":"publisher","first-page":"134.2","DOI":"10.4049\/jimmunol.184.Supp.134.2","volume":"184","author":"N Arbour","year":"2010","unstructured":"Arbour, N., Schneider, R., Yaneva, T. & Beauseigle, D. IL-27 promotes Tc1 polarization of human CD8 T lymphocytes and enhances their proliferation and effector functions (134.2). J. Immunol. 184, 134.2\u20132 (2010).","journal-title":"J. Immunol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01678-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:32:37Z","timestamp":1786919557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01678-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01678-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK has served in advisory capacities for Takeda and Janssen Pharmaceuticals on dengue. EEO has served in various advisory capacities for Sanofi Pasteur, Takeda, MSD, Janssen Pharmaceuticals, Novartis and Arcturus Therapeutics on dengue\/vaccines. All other authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"443"}}